Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists Reply

被引：0
|
作者：
Mensah, Michael O. [1 ]
Freitas, Daniel J. [2 ]
Cartwright, Joseph R. [3 ]
机构：
[1] Yale Univ, New Haven, CT 06520 USA
[2] San Francisco Dept Publ Hlth, San Francisco, CA USA
[3] Alameda Hlth Syst, Oakland, CA USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2024年 / 391卷 / 08期
关键词：
MORTALITY;
D O I：
10.1056/NEJMc2407932
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
To the Editor: The distribution framework for glucagon-like peptide-1 (GLP-1) receptor agonists proposed by Emanuel et al. in their Perspective article (May 30 issue)(1) considers potential years of life lost (PYLL) from obesity-related disease, but not race. How can clinicians and policymakers implement this framework "irrespective of factors such as race" (Table 1 in the article) when race and ethnic group are strongly associated with both PYLL and the risk of obesity-related disease? The PYLL metric - life expectancy minus the age at which a person dies - is seldom used in clinical medicine. But PYLL and life expectancy are . . .
引用
下载
收藏
页码：775 / 776
页数：2
相关论文
共 50 条
  • [41] Biology of incretins: GLP-1 and GIP
    Baggio, Laurie L.
    Drucker, Daniel J.
    GASTROENTEROLOGY, 2007, 132 (06) : 2131 - 2157
  • [42] Circulation and degradation of GIP and GLP-1
    Deacon, CF
    HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 761 - 765
  • [43] Extrapancreatic effects of GIP and GLP-1
    Vella, A
    Rizza, RA
    HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 830 - 836
  • [44] GLP-1 RECEPTOR VARIANTS MARKEDLY DIFFERENTIATE GLYCAEMIC RESPONSE TO GLP-1 RECEPTOR AGONISTS: A DIRECT STUDY
    Dawed, A. Y.
    Mari, A.
    McDonald, T. J.
    Hong, M. -G
    Sharma, S.
    Robertson, N. R.
    Mahajan, A.
    Walker, M.
    Gough, S.
    Zhou, K.
    Forgie, I
    Ruetten, H.
    Jones, A. G.
    Pearson, E. R.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 13 - 14
  • [45] GLP-1 receptor variants markedly differentiate glycaemic response to GLP-1 receptor agonists: a DIRECT study
    Dawed, A. Y.
    Mari, A.
    McDonald, T. J.
    Hong, M. G.
    Sharma, S.
    Robertson, N. R.
    Mahajan, A.
    Walker, M.
    Gough, S.
    Zhou, K.
    Forgie, I.
    Ruetten, H.
    Jones, A. G.
    Pearson, E. R.
    DIABETOLOGIA, 2017, 60 : S393 - S393
  • [46] Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment
    Trapp, Stefan
    Brierley, Daniel, I
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (04) : 557 - 570
  • [47] GLP-1 Agonists for Obesity
    Langland, James T.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024,
  • [48] GLP-1 Agonists for Obesity
    Kurian, Marina
    Rogers, Ann M.
    Peterson, Richard M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024,
  • [49] GLP-1 Agonists for Obesity
    Dellgren, Johan
    Emanuel, Ezekiel J.
    Persad, Govind
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024,
  • [50] GLP-1 receptor Gs-cotransfection: A new tool in screening for GLP-1 agonists.
    Knudsen, LB
    Wulff, BS
    DIABETOLOGIA, 1997, 40 : 1459 - 1459
12345